JP2023159335A5 - - Google Patents

Download PDF

Info

Publication number
JP2023159335A5
JP2023159335A5 JP2023135767A JP2023135767A JP2023159335A5 JP 2023159335 A5 JP2023159335 A5 JP 2023159335A5 JP 2023135767 A JP2023135767 A JP 2023135767A JP 2023135767 A JP2023135767 A JP 2023135767A JP 2023159335 A5 JP2023159335 A5 JP 2023159335A5
Authority
JP
Japan
Prior art keywords
antibody
drug
drug conjugate
conjugated
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023135767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023159335A (ja
Filing date
Publication date
Priority claimed from JP2019546364A external-priority patent/JP7337698B2/ja
Application filed filed Critical
Publication of JP2023159335A publication Critical patent/JP2023159335A/ja
Publication of JP2023159335A5 publication Critical patent/JP2023159335A5/ja
Pending legal-status Critical Current

Links

JP2023135767A 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体 Pending JP2023159335A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762465129P 2017-02-28 2017-02-28
US62/465,129 2017-02-28
US201762561151P 2017-09-20 2017-09-20
US62/561,151 2017-09-20
JP2019546364A JP7337698B2 (ja) 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体
PCT/US2018/020206 WO2018160683A1 (en) 2017-02-28 2018-02-28 Cysteine mutated antibodies for conjugation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019546364A Division JP7337698B2 (ja) 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体

Publications (2)

Publication Number Publication Date
JP2023159335A JP2023159335A (ja) 2023-10-31
JP2023159335A5 true JP2023159335A5 (OSRAM) 2024-03-04

Family

ID=63370994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019546364A Active JP7337698B2 (ja) 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体
JP2023135767A Pending JP2023159335A (ja) 2017-02-28 2023-08-23 コンジュゲート化のためのシステイン突然変異抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019546364A Active JP7337698B2 (ja) 2017-02-28 2018-02-28 コンジュゲート化のためのシステイン突然変異抗体

Country Status (13)

Country Link
US (1) US11938194B2 (OSRAM)
EP (1) EP3589320A4 (OSRAM)
JP (2) JP7337698B2 (OSRAM)
KR (1) KR102697394B1 (OSRAM)
CN (1) CN110352074B (OSRAM)
AU (1) AU2018227807B2 (OSRAM)
CA (1) CA3052837A1 (OSRAM)
IL (1) IL268959B2 (OSRAM)
MX (1) MX2019010028A (OSRAM)
NZ (1) NZ756323A (OSRAM)
SG (1) SG11201907288RA (OSRAM)
TW (1) TW201840586A (OSRAM)
WO (1) WO2018160683A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
KR20220079590A (ko) 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024052684A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use
CN115850449A (zh) * 2022-09-29 2023-03-28 苏州智核生物医药科技有限公司 抗体和缀合物
WO2025058000A1 (ja) 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び／又は診断用医薬組成物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2009538273A (ja) 2006-04-14 2009-11-05 トルビオン ファーマシューティカルズ， インコーポレイテッド 改造されたＦＣエフェクター機能を持つ、免疫グロブリン・ヒンジ領域とＦｃ領域とを備える結合タンパク質
WO2007119796A1 (ja) * 2006-04-14 2007-10-25 Medical And Biological Laboratories Co., Ltd. エフェクター機能を有するポリペプチド変異体
MX2008015771A (es) 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
FR2912465B1 (fr) 2007-02-12 2013-08-02 Jean Melchior Moteur a combustion interne alimente par un melange gazeux homogene pauvre.
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
JP5427348B2 (ja) * 2007-10-12 2014-02-26 株式会社医学生物学研究所 エフェクター機能が向上した抗体
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
CN103119064B (zh) 2010-08-10 2018-09-04 葛莱高托普有限公司 Fab糖基化抗体
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013047752A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CA2900755C (en) * 2013-02-08 2021-07-20 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
CN106659800A (zh) 2014-03-12 2017-05-10 诺华股份有限公司 用于修饰抗体以制备免疫缀合物的特定位点
SMT201900160T1 (it) 2014-04-11 2019-05-10 Medimmune Llc Composti coniugati comprendenti anticorpi ingegnerizzati con cisteina
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
CN106659783A (zh) * 2014-06-20 2017-05-10 艾比吉诺米克斯国际股份有限公司 Her2抗体‑药物缀合物
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
TW201625688A (zh) * 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
CN107124870A (zh) 2014-09-17 2017-09-01 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
JP2017533887A (ja) * 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
TWI703160B (zh) 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
EP3390443A4 (en) 2015-12-18 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
EP3525826B1 (en) 2016-10-11 2020-07-22 Byondis B.V Non-linear self-immolative linkers and conjugates thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20200095327A1 (en) 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor

Similar Documents

Publication Publication Date Title
TWI680765B (zh) 自行穩定之接合劑共軛物
JP6328649B2 (ja) 薬物−タンパク質コンジュゲート
CA1336496C (en) Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
CN108465112B (zh) 自稳定接头偶联物
JP2020122023A5 (OSRAM)
AU2006269940B2 (en) Beta-glucuronide-linker drug conjugates
JP2022530524A5 (OSRAM)
JP6328648B2 (ja) 新規薬物−タンパク質コンジュゲート
JP2008500961A5 (OSRAM)
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
US20250127793A1 (en) Conjugates of surrogate light chain constructs
EP3165237B1 (en) Antibody-drug conjugate (adc) and method for forming the same
Sijbrandi et al. A novel platinum (II)–based bifunctional ADC linker benchmarked using 89Zr-Desferal and Auristatin F–conjugated Trastuzumab
EA038512B1 (ru) Конъюгаты майтанзиноидов и их терапевтическое применение
BR112020018948A2 (pt) Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
JP2020509010A5 (OSRAM)
HRP20230027T1 (hr) Konjugati protutijela s lijekom i njihova upotreba u liječenju raka
CN111655295A (zh) 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
WO2004050711A3 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
Gaál et al. Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide
IL273384B2 (en) Methods of preventing methionine oxidation in immunoconjugates
JP2020534326A5 (OSRAM)
JP2024506708A5 (OSRAM)